| Entry |
|
|---|
| Name |
Sevabertinib hydrate (JAN);
Hyrnuo (TN) |
|---|
| Product |
|
|---|
| Formula |
C24H25ClN4O5. xH2O
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG01633 CYP3A/CYP3A4 substrate
|
|---|
| Remark |
| Product (DG03348): | D13116<US> |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Non-squamous non-small cell lung cancer (HER2 activating mutation) [DS: H00014] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Network |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01EH06 Sevabertinib
D13116 Sevabertinib hydrate (JAN) <US>
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03348 Sevabertinib
D13116 Sevabertinib hydrate
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG03348 Sevabertinib
D13116 Sevabertinib hydrate
DG01633 CYP3A/CYP3A4 substrate
DG03348 Sevabertinib
D13116 Sevabertinib hydrate
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR
D13116 Sevabertinib hydrate (JAN) <US>
ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v2]
D13116 Sevabertinib hydrate (JAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D13116
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D13116
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D13116
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D13116
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03348 Sevabertinib
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG03348 Sevabertinib
DG01633 CYP3A/CYP3A4 substrate
DG03348 Sevabertinib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 35
1 C8y C 21.6006 -14.8198
2 C8y C 21.6006 -16.2179
3 C5x C 22.7890 -16.9170
4 N1x N 24.0473 -16.2179
5 C1x C 24.0473 -14.8198
6 C1x C 22.7890 -14.1208
7 N4x N 20.2724 -14.4004
8 C8y C 19.4335 -15.5189
9 C8y C 20.2724 -16.6374
10 C8y C 18.0355 -15.5189
11 C8y C 17.3364 -14.2606
12 C8x C 15.9383 -14.2606
13 N5x N 15.2393 -15.5189
14 C8x C 15.9383 -16.7073
15 C8x C 17.3364 -16.7073
16 O2a O 18.0355 -13.0722
17 C1b C 17.3364 -11.8838
18 C1y C 15.9383 -11.8838
19 C1x C 15.2393 -10.6954
20 O2x O 13.8412 -10.6954
21 C1x C 13.1421 -11.9537
22 C1x C 13.8412 -13.1421
23 O2x O 15.2393 -13.1421
24 O5x O 22.7890 -18.3151
25 N1b N 19.8530 -17.9655
26 C8y C 18.4549 -18.2452
27 C8x C 17.5461 -17.1966
28 C8x C 16.1480 -17.4762
29 C8x C 15.7286 -18.8044
30 C8y C 16.6374 -19.8530
31 C8y C 18.0355 -19.5734
32 O2a O 18.9442 -20.6219
33 C1a C 20.2724 -20.3423
34 X Cl 16.2179 -21.1812
35 O0 O 27.0900 -20.5100
BOND 38
1 1 2 2
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 1 7 1
8 7 8 1
9 8 9 2
10 2 9 1
11 8 10 1
12 10 11 2
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 10 15 1
18 11 16 1
19 16 17 1
20 18 17 1 #Up
21 18 19 1
22 19 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 18 23 1
27 3 24 2
28 9 25 1
29 25 26 1
30 26 27 2
31 27 28 1
32 28 29 2
33 29 30 1
34 30 31 2
35 26 31 1
36 31 32 1
37 32 33 1
38 30 34 1
BRACKET 1 25.0600 -21.5600 25.0600 -19.4600
1 27.8600 -19.4600 27.8600 -21.5600
1 x
ORIGINAL 1 35
REPEAT 1
|
|---|
